Biovie Inc. has filed an amendment to its prospectus supplement, indicating a reduction in the amount of common stock it plans to offer. The company has adjusted its offering to a total of $285,000, down from a previous amount of $1,225,000. This move is significant as it reflects Biovie's ongoing strategy to navigate the current market conditions.

Founded in Nevada and operating under the SIC code 2834, which pertains to Pharmaceutical Preparations, Biovie Inc. is a smaller reporting company listed on Nasdaq with the tickers BIVI and BIVIW. The most recent filing was made on November 4, 2026, and it follows a series of recent filings, including a prospectus dated June 29, 2026.

According to the filing, "We are filing this Amendment to amend the Prior Prospectus to reduce the amount of our common stock we may offer and sell under the Sales Agreement to up to an aggregate of $285,000." This amendment comes as part of a sales agreement with A.G.P./Alliance Global Partners, which acts as the sales agent for the offering.

The adjustment in the offering amount may affect various stakeholders, including current and potential investors, as it highlights the company's cautious approach to capital raising in a fluctuating market environment. As of November 4, 2026, the aggregate market value of Biovie's common stock held by non-affiliates was approximately $17.9 million.

What's next for Biovie remains unclear, as the filing does not specify future actions following this amendment. Investors and analysts will be watching closely for any further updates or filings that may provide additional insights into the company's strategic direction.